• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® VIABAHN® ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE; SYSTEM, ENDO GRAFT, ARTERIOVENOUS DIALYSIS ACCESS CIRCUIT STENOSIS TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® VIABAHN® ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE; SYSTEM, ENDO GRAFT, ARTERIOVENOUS DIALYSIS ACCESS CIRCUIT STENOSIS TREATMENT Back to Search Results
Device Problem Insufficient Information (3190)
Patient Problems Bacterial Infection (1735); Thrombosis/Thrombus (4440)
Event Date 09/02/2020
Event Type  Injury  
Manufacturer Narrative
(b)(4).Cbas® heparin surface incorporates cbas-heparin manufactured from (b)(4), which is covalently bound to the device surface and is essentially non-eluting.Citation: the journal of vascular access 1¿8.The author(s) 2020 article reuse guidelines: sagepub.Com/journals-permissions.Doi: 10.1177/1129729820961955.Journals.Sagepub.Com/home/jva.
 
Event Description
The following information was received through literature ¿use of the viabahn covered stent for the treatment of venous rupture during interventions of dysfunctional or thrombosed hemodialysis vascular access¿ published by the journal of vascular access 1¿8.The study was to report the immediate outcomes and patency rates of a covered stent to rescue angioplasty-related venous rupture of hemodialysis vascular access.A total of 52 vessel ruptures (21 fistulas, 31 grafts) salvaged by using viabahn covered stents were enrolled from january 2013 to december 2018.The results state that in one patient, the bleeding was successfully stopped, but the procedure was ultimately unsuccessful due to a large thrombus burden.Anatomical success of the pta procedure was defined as <30% residual stenosis at the stent area.In another patient, the procedure was successful; however, recurrent thrombosis developed before the dialysis session.One patient had vascular access infection within 1 month after the procedure, and the av graft was removed.
 
Manufacturer Narrative
Update g4.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® VIABAHN® ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE
Type of Device
SYSTEM, ENDO GRAFT, ARTERIOVENOUS DIALYSIS ACCESS CIRCUIT STENOSIS TREATMENT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL ECHO RIDGE B/P
3250 w. kiltie lane
flagstaff AZ 86005
Manufacturer Contact
pixie xi
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key12369066
MDR Text Key268245742
Report Number2017233-2021-02309
Device Sequence Number1
Product Code PFV
Combination Product (y/n)Y
Reporter Country CodeTW
PMA/PMN Number
P130006
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 11/22/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received08/26/2021
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received08/14/2021
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age76 YR
Patient SexFemale
-
-